Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
Conclusion: The 5-year US postmarketing safety data of dalfampridine-ER is consistent with the safety profile observed in clinical trials. Incidence of reported seizures remained stable over time. Since commercial availability in March 2010, a warning regarding the risk of anaphylaxis and severe allergic reactions was added to the US prescribing information. Keywords: dalfampridine, fampridine, multiple sclerosis, adverse events, postmarketing safety
Source: Drug, Healthcare and Patient Safety - Category: Drugs & Pharmacology Tags: Drug, Healthcare and Patient Safety Source Type: research
More News: Allergy & Immunology | Anaphylactic Shock | Clinical Trials | Drugs & Pharmacology | Headache | Insomnia | Migraine | Multiple Sclerosis | Urinary Tract Infections | Warnings